Washington University School of Medicine’s MM3122 Crushes Remdesivir in Preclinical Lab Tests: ProteXase Therapeutics Secures IP

Preclinical researchers at Washington University School of Medicine in St. Louis (WUSTL) recently announced the development of MM3122, a chemical compound targeting the human protein known as transmembrane serine protease 2 (TMPRSS2). All known coronaviruses exploit this protein to penetrate and infect human cells. MM32122 destroyed remdesivir in a head-on comparison at the WUSTL lab. Specifically, the WUSTL preclinical compound did a superior job protecting lab-grown human cells from viral damage caused by SARS-CoV-2. Conducting preclinical safety tests on mice, large doses of the novel, pre-clinical-stage drug were administered for seven days with no material safety issues identified. Preclinical research also indicates the compound works against the first coronavirus (SARS-CoV) as well as against Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV). The researchers believe that this compound has the potential to prevent infection or reduce the severity of COVID-19 if given early in the course of an infection. The leading researcher and author of the study report, James W. Janetka, co-founded a biotech startup venture which has licensed the technology t...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee